keyword
MENU ▼
Read by QxMD icon Read
search

Pseudoprogression

keyword
https://www.readbyqxmd.com/read/28428211/imaging-manifestations-of-pseudoprogression-in-metastatic-melanoma-nodes-injected-with-talimogene-laherparepvec-initial-experience
#1
C Zamora, M Lopez, F Cunningham, F Collichio, M Castillo
Talimogene laherparepvec is an oncolytic virus recently approved for targeted treatment of advanced melanoma. Because of an inflammatory reaction, treated lesions may increase in size and develop infiltrative margins that can be construed as disease progression or extracapsular spread. In this report, we describe our initial experience imaging the response of metastatic nodes injected with talimogene laherparepvec. Six of 12 nodes (50%) showed growth from baseline followed by decreased size, 5 of 12 nodes (42%) showed a downward size trend, and 1 node showed continued increase in size...
April 20, 2017: AJNR. American Journal of Neuroradiology
https://www.readbyqxmd.com/read/28384170/differentiation-of-pseudoprogression-and-real-progression-in-glioblastoma-using-adc-parametric-response-maps
#2
Caroline Reimer, Katerina Deike, Markus Graf, Peter Reimer, Benedikt Wiestler, Ralf Omar Floca, Philipp Kickingereder, Heinz-Peter Schlemmer, Wolfgang Wick, Martin Bendszus, Alexander Radbruch
PURPOSE: The purpose of this study was to investigate whether a voxel-wise analysis of apparent diffusion coefficient (ADC) values may differentiate between progressive disease (PD) and pseudoprogression (PsP) in patients with high-grade glioma using the parametric response map, a newly introduced postprocessing tool. METHODS: Twenty-eight patients with proven PD and seven patients with PsP were identified in this retrospective feasibility study. For all patients ADC baseline and follow-up maps on four subsequent MRIs were available...
2017: PloS One
https://www.readbyqxmd.com/read/28382534/pseudoprogression-radionecrosis-inflammation-or-true-tumor-progression-challenges-associated-with-glioblastoma-response-assessment-in-an-evolving-therapeutic-landscape
#3
REVIEW
Benjamin M Ellingson, Caroline Chung, Whitney B Pope, Jerrold L Boxerman, Timothy J Kaufmann
The wide variety of treatment options that exist for glioblastoma, including surgery, ionizing radiation, anti-neoplastic chemotherapies, anti-angiogenic therapies, and active or passive immunotherapies, all may alter aspects of vascular permeability within the tumor and/or normal parenchyma. These alterations manifest as changes in the degree of contrast enhancement or T2-weighted signal hyperintensity on standard anatomic MRI scans, posing a potential challenge for accurate radiographic response assessment for identifying anti-tumor effects...
April 5, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28371397/delayed-pseudoprogression-of-lung-adenocarcinoma-accompanied-with-interstitial-lung-disease-during-chemotherapy-after-nivolumab-treatment
#4
Toru Kumagai, Madoka Kimura, Takako Inoue, Motohiro Tamiya, Kazumi Nishino, Fumio Imamura
A 62-year-old Japanese female with primary lung adenocarcinoma received seven cycles of nivolumab as an eighth line of chemotherapy until she presented with hemoptysis. After transcatheter arterial embolization therapy, she received subsequent chemotherapy with paclitaxel and S-1. Four weeks later, a chest computed tomography examination revealed infiltrative shadows mainly in the right lung field, in addition to enlargement of the lung metastasis in the right middle lung lobe. Bronchofiberscopic examination revealed infiltration of lymphocytes without any malignant cells in the right segment 1 of the lung, which suggested interstitial lung disease...
March 30, 2017: Thoracic Cancer
https://www.readbyqxmd.com/read/28367384/pilocytic-astrocytoma-enlargement-following-irradiation-relapse-or-pseudoprogression
#5
Yury Trunin, Andrey V Golanov, Valery V Kostjuchenko, Mikhail Galkin, Alexander N Konovalov
Pilocytic astrocytomas are the most common gliomas (World Health Organization (WHO) grade 1) in children. According to many authors, stereotactic irradiation (radiotherapy and radiosurgery) is an effective method that provides a prolonged, recurrence-free survival in patients who have had partial tumor removal or in patients with an unresectable tumor. We present a case of a patient with midbrain pilocytic astrocytoma that enlarged considerably in the first six months after irradiation and then diminished in size during the next six months without any antitumor treatment...
February 21, 2017: Curēus
https://www.readbyqxmd.com/read/28349351/advanced-mri-techniques-in-the-monitoring-of-treatment-of-gliomas
#6
REVIEW
Harpreet Hyare, Steffi Thust, Jeremy Rees
With advances in treatments and survival of patients with glioblastoma (GBM), it has become apparent that conventional imaging sequences have significant limitations both in terms of assessing response to treatment and monitoring disease progression. Both 'pseudoprogression' after chemoradiation for newly diagnosed GBM and 'pseudoresponse' after anti-angiogenesis treatment for relapsed GBM are well-recognised radiological entities. This in turn has led to revision of response criteria away from the standard MacDonald criteria, which depend on the two-dimensional measurement of contrast-enhancing tumour, and which have been the primary measure of radiological response for over three decades...
March 2017: Current Treatment Options in Neurology
https://www.readbyqxmd.com/read/28296759/the-diagnostic-performance-of-perfusion-mri-for-differentiating-glioma-recurrence-from-pseudoprogression-a-meta-analysis
#7
Bing Wan, Siqi Wang, Mengqi Tu, Bo Wu, Ping Han, Haibo Xu
BACKGROUND: The purpose of this meta-analysis was to evaluate the diagnostic accuracy of perfusion magnetic resonance imaging (MRI) as a method for differentiating glioma recurrence from pseudoprogression. METHODS: The PubMed, Embase, Cochrane Library, and Chinese Biomedical databases were searched comprehensively for relevant studies up to August 3, 2016 according to specific inclusion and exclusion criteria. The quality of the included studies was assessed according to the quality assessment of diagnostic accuracy studies (QUADAS-2)...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28282372/automated-fluorescent-miscroscopic-image-analysis-of-ptbp1-expression-in-glioma
#8
Behiye Kaya, Evgin Goceri, Aline Becker, Brad Elder, Vinay Puduvalli, Jessica Winter, Metin Gurcan, José Javier Otero
Multiplexed immunofluorescent testing has not entered into diagnostic neuropathology due to the presence of several technical barriers, amongst which includes autofluorescence. This study presents the implementation of a methodology capable of overcoming the visual challenges of fluorescent microscopy for diagnostic neuropathology by using automated digital image analysis, with long term goal of providing unbiased quantitative analyses of multiplexed biomarkers for solid tissue neuropathology. In this study, we validated PTBP1, a putative biomarker for glioma, and tested the extent to which immunofluorescent microscopy combined with automated and unbiased image analysis would permit the utility of PTBP1 as a biomarker to distinguish diagnostically challenging surgical biopsies...
2017: PloS One
https://www.readbyqxmd.com/read/28274394/pseudoprogression-of-a-spinal-metastasis-after-stereotactic-ablative-body-radiation-therapy-and-immune-checkpoint-therapy
#9
Sachin R Jhawar, Ann W Silk, Sharad Goyal
No abstract text is available yet for this article.
March 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/28176884/impact-of-including-peritumoral-edema-in-radiotherapy-target-volume-on-patterns-of-failure-in-glioblastoma-following-temozolomide-based-chemoradiotherapy
#10
Seo Hee Choi, Jun Won Kim, Jee Suk Chang, Jae Ho Cho, Se Hoon Kim, Jong Hee Chang, Chang-Ok Suh
We assessed the impact of including peritumoral edema in radiotherapy volumes on recurrence patterns among glioblastoma multiforme (GBM) patients treated with standard chemoradiotherapy (CRT). We analyzed 167 patients with histologically confirmed GBM who received temozolomide (TMZ)-based CRT between May 2006 and November 2012. The study cohort was divided into edema (+) (n = 130) and edema (-) (n = 37) groups, according to whether the entire peritumoral edema was included. At a median follow-up of 20 months (range, 2-99 months), 118 patients (71%) experienced progression/recurrence (infield: 69%; marginal: 26%; outfield: 16%; CSF seeding: 12%)...
February 8, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28175467/219%C3%A2-liquid-biopsy-can-distinguish-recurrent-glioblastomas-from-pseudoprogression-and-radiation-necrosis-after-concurrent-radiochemotherapy
#11
Andrew E Sloan, David Soler, Anne B Young, Kelvin D Cooper, Thomas McCormic
No abstract text is available yet for this article.
August 1, 2016: Neurosurgery
https://www.readbyqxmd.com/read/28143434/combination-of-ivim-dwi-and-3d-asl-for-differentiating-true-progression-from-pseudoprogression-of-glioblastoma-multiforme-after-concurrent-chemoradiotherapy-study-protocol-of-a-prospective-diagnostic-trial
#12
Zhi-Cheng Liu, Lin-Feng Yan, Yu-Chuan Hu, Ying-Zhi Sun, Qiang Tian, Hai-Yan Nan, Ying Yu, Qian Sun, Wen Wang, Guang-Bin Cui
BACKGROUND: Standard therapy for Glioblastoma multiforme (GBM) involves maximal safe tumor resection followed with radiotherapy and concurrent adjuvant temozolomide. About 20 to 30% patients undergoing their first post-radiation MRI show increased contrast enhancement which eventually recovers without any new treatment. This phenomenon is referred to as pseudoprogression. Differentiating tumor progression from pseudoprogression is critical for determining tumor treatment, yet this capacity remains a challenge for conventional magnetic resonance imaging (MRI)...
February 1, 2017: BMC Medical Imaging
https://www.readbyqxmd.com/read/28121940/not-only-for-melanoma-subcutaneous-pseudoprogression-in-lung-squamous-cell-carcinoma-treated-with-nivolumab-a-case-report
#13
Michal Sarfaty, Assaf Moore, Elizabeth Dudnik, Nir Peled
RATIONALE: Pseudoprogression, that is, initial tumor growth followed by subsequent tumor regression, has been well described for immunomodulation therapy in melanoma patients. This phenomenon is not well defined in lung cancer. Nivolumab, an anti-PD-1 monoclonal antibody, was recently approved for nonsmall cell lung cancer (NSCLC) as a second-line therapy. PATIENT CONCERNS AND DIAGNOSIS: We present a patient with squamous NSCLC, suffering from multiple bone and subcutaneous metastases...
January 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28108885/modified-criteria-for-radiographic-response-assessment-in-glioblastoma-clinical-trials
#14
REVIEW
Benjamin M Ellingson, Patrick Y Wen, Timothy F Cloughesy
Radiographic endpoints including response and progression are important for the evaluation of new glioblastoma therapies. The current RANO criteria was developed to overcome many of the challenges identified with previous guidelines for response assessment, however, significant challenges and limitations remain. The current recommendations build on the strengths of the current RANO criteria, while addressing many of these limitations. Modifications to the current RANO criteria include suggestions for volumetric response evaluation, use contrast enhanced T1 subtraction maps to increase lesion conspicuity, removal of qualitative non-enhancing tumor assessment requirements, use of the post-radiation time point as the baseline for newly diagnosed glioblastoma response assessment, and "treatment-agnostic" response assessment rubrics for identifying pseudoprogression, pseudoresponse, and a confirmed durable response in newly diagnosed and recurrent glioblastoma trials...
January 20, 2017: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://www.readbyqxmd.com/read/28066810/dynamic-susceptibility-contrast-mri-quantification-software-tool-development-and-evaluation
#15
Panagiotis Korfiatis, Timothy L Kline, Zachary S Kelm, Rickey E Carter, Leland S Hu, Bradley J Erickson
Relative cerebral blood volume (rCBV) is a magnetic resonance imaging biomarker that is used to differentiate progression from pseudoprogression in patients with glioblastoma multiforme, the most common primary brain tumor. However, calculated rCBV depends considerably on the software used. Automating all steps required for rCBV calculation is important, as user interaction can lead to increased variability and possible inaccuracies in clinical decision-making. Here, we present an automated tool for computing rCBV from dynamic susceptibility contrast-magnetic resonance imaging that includes leakage correction...
December 2016: Tomography: a Journal for Imaging Research
https://www.readbyqxmd.com/read/28061488/the-use-of-mr-perfusion-imaging-in-the-evaluation-of-tumor-progression-in-gliomas
#16
Brian Snelling, Ashish H Shah, Simon Buttrick, Ronald Benveniste
OBJECTIVE: Diagnosing tumor progression and pseudoprogression remains challenging for many clinicians. Accurate recognition of these findings remains paramount given necessity of prompt treatment. However, no consensus has been reached on the optimal technique to discriminate tumor progression. We sought to investigate the role of magnetic resonance perfusion (MRP) to evaluate tumor progression in glioma patients. METHODS: An institutional retrospective review of glioma patients undergoing MRP with concurrent clinical follow up visit was performed...
January 1, 2017: Journal of Korean Neurosurgical Society
https://www.readbyqxmd.com/read/28030820/unsupervised-consensus-cluster-analysis-of-18f-fluoroethyl-l-tyrosine-positron-emission-tomography-identified-textural-features-for-the-diagnosis-of-pseudoprogression-in-high-grade-glioma
#17
Sied Kebir, Zain Khurshid, Florian C Gaertner, Markus Essler, Elke Hattingen, Rolf Fimmers, Björn Scheffler, Ulrich Herrlinger, Ralph A Bundschuh, Martin Glas
RATIONALE: Timely detection of pseudoprogression (PSP) is crucial for the management of patients with high-grade glioma (HGG) but remains difficult. Textural features of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (FET-PET) mirror tumor uptake heterogeneity; some of them may be associated with tumor progression. METHODS: Fourteen patients with HGG and suspected of PSP underwent FET-PET imaging. A set of 19 conventional and textural FET-PET features were evaluated and subjected to unsupervised consensus clustering...
January 31, 2017: Oncotarget
https://www.readbyqxmd.com/read/28018599/immune-related-response-assessment-during-pd-1-inhibitor-therapy-in-advanced-non-small-cell-lung-cancer-patients
#18
Mizuki Nishino, Nikhil H Ramaiya, Emily S Chambers, Anika E Adeni, Hiroto Hatabu, Pasi A Jänne, F Stephen Hodi, Mark M Awad
BACKGROUND: Tumor response characteristics using immune-related RECIST1.1 (irRECIST1.1) in advanced non-small-cell lung cancer (NSCLC) patients treated with nivolumab monotherapy in the clinical setting have not been previously described with a direct comparison with the assessments according to the conventional RECIST1.1. METHODS: Fifty-six advanced NSCLC patients treated with nivolumab monotherapy after its Food and Drug Administration (FDA) approval were retrospectively studied...
2016: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/27998280/misleading-early-blood-volume-changes-obtained-using-ferumoxytol-based-magnetic-resonance-imaging-perfusion-in-high-grade-glial-neoplasms-treated-with-bevacizumab
#19
Joao Prola Netto, Daniel Schwartz, Csanad Varallyay, Rongwei Fu, Bronwyn Hamilton, Edward A Neuwelt
BACKGROUND: Neovascularization, a distinguishing trait of high-grade glioma, is a target for anti-angiogenic treatment with bevacizumab (BEV). This study sought to use ferumoxytol-based dynamic susceptibility contrast magnetic resonance imaging (MRI) to clarify perfusion and relative blood volume (rCBV) changes in glioma treated with BEV and to determine potential impact on clinical management. METHODS: 16 high grade glioma patients who received BEV following post-chemoradiation radiographic or clinical progression were included...
December 20, 2016: Fluids and Barriers of the CNS
https://www.readbyqxmd.com/read/27987588/report-of-two-cases-of-pseudoprogression-in-patients-with-non-small-cell-lung-cancer-treated-with-nivolumab-including-histological-analysis-of-one-case-after-tumor-regression
#20
Junko Tanizaki, Hidetoshi Hayashi, Masatomo Kimura, Kaoru Tanaka, Masayuki Takeda, Shigeki Shimizu, Akihiko Ito, Kazuhiko Nakagawa
The recent approval of nivolumab and other immune-checkpoint inhibitors for the treatment of certain solid tumors including non-small cell lung cancer (NSCLC) has transformed cancer therapy. However, it will be important to characterize effects of such agents not seen with classical cytotoxic drugs or other targeted therapeutics. We here report two cases of NSCLC showing so-called pseudoprogression during nivolumab treatment. In both cases, imaging assessment revealed that liver metastatic lesions initially progressed but subsequently shrank during continuous nivolumab administration, with treatment also resulting in a decline in serum levels of carcinoembryonic antigen...
December 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
keyword
keyword
12545
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"